519 related articles for article (PubMed ID: 28608617)
1. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Gouda M; Iijima H; Watanabe Y
Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
5. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
[TBL] [Abstract][Full Text] [Related]
6. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
Hong S; Park CY; Han KA; Chung CH; Ku BJ; Jang HC; Ahn CW; Lee MK; Moon MK; Son HS; Lee CB; Cho YW; Park SW
Diabetes Obes Metab; 2016 May; 18(5):528-32. PubMed ID: 26749529
[TBL] [Abstract][Full Text] [Related]
8. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Iijima H; Watanabe Y; Gouda M
Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
[TBL] [Abstract][Full Text] [Related]
10. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
Kadowaki T; Inagaki N; Watada H; Sasaki K; Mori-Anai K; Iwasaki T; Teranishi T
Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
[TBL] [Abstract][Full Text] [Related]
11. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
Fushimi Y; Obata A; Sanada J; Iwamoto Y; Mashiko A; Horiya M; Mizoguchi-Tomita A; Nishioka M; Kan Y; Kinoshita T; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Res; 2020; 2020():4861681. PubMed ID: 32337293
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
[TBL] [Abstract][Full Text] [Related]
13. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
[TBL] [Abstract][Full Text] [Related]
15. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
[TBL] [Abstract][Full Text] [Related]
16. Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.
Wada N; Mori K; Nakagawa C; Sawa J; Kumeda Y; Shoji T; Emoto M; Inaba M
J Diabetes Complications; 2015; 29(8):1310-3. PubMed ID: 26298521
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.
Harashima SI; Inagaki N; Kondo K; Maruyama N; Otsuka M; Kawaguchi Y; Watanabe Y
Diabetes Obes Metab; 2018 Jul; 20(7):1770-1775. PubMed ID: 29473709
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
Kadowaki T; Kondo K; Sasaki N; Miyayama K; Yokota S; Terata R; Gouda M
Expert Opin Pharmacother; 2017 Sep; 18(13):1291-1300. PubMed ID: 28741385
[TBL] [Abstract][Full Text] [Related]
19. Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
Cho KY; Nomoto H; Nakamura A; Kawata S; Sugawara H; Takeuchi J; Nagai S; Omori K; Tsuchida K; Miya A; Shigesawa I; Tsuchida K; Yanagiya S; Kameda H; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Nishimoto N; Atsumi T; Miyoshi H
J Diabetes Investig; 2021 Aug; 12(8):1417-1424. PubMed ID: 33421309
[TBL] [Abstract][Full Text] [Related]
20. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
Ceriello A; De Nigris V; Iijima H; Matsui T; Gouda M
Drugs; 2019 May; 79(7):733-750. PubMed ID: 30982160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
